You are here

Article info

Article menu
Download PDFPDF
EBM analysis
Mental health
Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

Authors

  • Ole Jakob Storebø Psychiatric Department, Center For Evidence Based Psychiatry, Psychiatric Research Unit, Slagelse, Denmark Department of Psychology, Faculty of Health Science, University of Southern Denmark, Odense, Denmark PubMed articlesGoogle scholar articles
  • Christian Gluud The Copenhagen Trial Unit (CTU), Centre for Clinical Intervention Research, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ole Jakob Storebø, Psychiatric Department, Center for Evidence Based Psychiatry, Psychiatric Research Unit, Slagelse 4000, Denmark; ojst{at}regionsjaelland.dk
View Full Text

Citation

Storebø OJ, Gluud C
Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile
BMJ Evidence-Based Medicine 2021;26:172-175.

Publication history

  • Accepted April 12, 2020
  • First published April 24, 2020.
Online issue publication 
January 10, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.